DrugPatentWatch Database Preview
AURYXIA Drug Profile
or, see our see our flat-rate plans
When do Auryxia patents expire, and when can generic versions of Auryxia launch?
This drug has one hundred and two patent family members in twenty-three countries.
The generic ingredient in AURYXIA is ferric citrate. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric citrate profile page.
Summary for AURYXIA
| International Patents: | 102 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 33 |
| Clinical Trials: | 5 |
| Patent Applications: | 3 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AURYXIA |
| DailyMed Link: | AURYXIA at DailyMed |
Pharmacology for AURYXIA
| Ingredient-type | Iron |
| Drug Class | Parenteral Iron Replacement Phosphate Binder |
| Mechanism of Action | Phosphate Chelating Activity |
Synonyms for AURYXIA
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt |
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt (1:?) |
| 1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron(2+) salt (2:3) |
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt |
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1) |
| 11084-12-1 |
| 1185-57-5 |
| 12386-83-3 |
| 12549-57-4 |
| 17217-76-4 (trihydrate) |
| 2-hydroxy-1,2,3-propanetricarboxylic acid iron salt |
| 2-hydroxypropane-1,2,3-tricarboxylate; iron(3+) |
| 23087-37-8 |
| 2338-05-8 |
| 2338-05-8 (unspecified iron salt) |
| 28633-45-6 |
| 28633-45-6 (unspecified iron(+3) salt) |
| 3522-50-7 |
| 3522-50-7 (Parent) |
| 3B1-003934 |
| 47516-89-2 |
| 57979-58-5 (dihydrate) |
| 6043-74-9 |
| 62709-48-2 |
| 63G354M39Z |
| 7705-15-9 |
| A832727 |
| AC1L1UYI |
| ACM28633456 |
| AKOS015918266 |
| AN-19905 |
| C6H5FeO7 |
| CCRIS 6843 |
| Citric acid iron(III) salt |
| Citric acid, iron salt |
| Citric acid, iron(3+) salt |
| Citric acid, iron(3+) salt (1:1) |
| CTK1C2869 |
| D04CJL |
| DB09162 |
| DTXSID0037657 |
| EINECS 222-536-6 |
| EINECS 249-117-0 |
| Fe(III)-citrate complex (1:1) |
| FERRIC CITRATE |
| Ferric citrate (VAN) |
| Ferric citrate [USAN] |
| FERRICCITRATE |
| ferrum citricum |
| FT-0626407 |
| FT-0627304 |
| FT-0652224 |
| H260 |
| Hyperphosphatemia therapy, Panion/Keryx |
| I14-60931 |
| I14-8077 |
| Iron (III) citrate |
| Iron 2-hydroxy-1,2,3-propanetricarboxylate |
| Iron citrate |
| Iron citrate, FeC6H5O7 |
| Iron, (hydrogen citrato(3-))- |
| iron(3+) citrate |
| iron(3+) ion 2-hydroxypropane-1,2,3-tricarboxylate |
| iron(3+); 2-oxidanylpropane-1,2,3-tricarboxylate |
| Iron(III) citrate |
| Iron(III) citrate tribasic |
| Iron(III)-citrate |
| JTT 751 |
| JTT-751 |
| KRX-0502 |
| KS-0000108D |
| MCULE-2140052675 |
| Nephoxil |
| NPFOYSMITVOQOS-UHFFFAOYSA-K |
| NSC 112227 |
| OR020149 |
| OR253005 |
| PBF-1681 |
| SCHEMBL42945 |
| TR-037246 |
| TRA0022730 |
| UNII-63G354M39Z |
| Zerenex |
US Patents and Regulatory Information for AURYXIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET;ORAL | 205874-001 | Sep 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET;ORAL | 205874-001 | Sep 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET;ORAL | 205874-001 | Sep 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET;ORAL | 205874-001 | Sep 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Expired US Patents for AURYXIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Keryx Biopharms | AURYXIA | ferric citrate | TABLET;ORAL | 205874-001 | Sep 5, 2014 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for AURYXIA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,913,821 | Ferric organic compounds, uses thereof and methods of making same | ➤ Sign Up |
| 9,750,715 | Method of reversing, preventing, delaying or stabilizing soft tissue calcification | ➤ Sign Up |
| 9,889,113 | Method for reversing, preventing, delaying or stabilizing soft tissue calcification | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
or, see our see our flat-rate plans
International Patents for AURYXIA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Taiwan | I429428 | ➤ Sign Up |
| European Patent Office | 1931689 | ➤ Sign Up |
| New Zealand | 541991 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2007022435 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
